Last update Dec. 29, 2014


Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

On latest update, no relevant published data related to excretion into breast milk were found.

It is a product that has only mild or few side-effects when used at normal dose.

The absorption from ingested mother's milk to the infant's plasma is hampered by a low oral bioavailability, with this being a reason for a nil or minimal plasma level in the infant, except in prematures or soon after birth when absorption would be higher.


We do not have alternatives for Carbocisteine since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.


Variable Value Unit
Oral Bioavail. 10 %
Molecular weight 179 daltons
VD 0.9 l/Kg
Tmax 1.5 - 2 hours
2.5 - 3.1 hours


  1. Irish Medicines Board. Carbocisteine. Drug Summary. 2014 Full text (in our servers)
  2. AEMPS. Carbocisteina. Ficha técnica. 2012 Full text (in our servers)
  3. AEMPS. Carbocisteína. Ficha técnica. 1998 Full text (in our servers)

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM